louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05089578: Integrative Treatment Methods in COVID-19
Official title: Examination of the Use of Integrative Treatment Methods by Individuals Undergoing COVID-19 Acording to the Health Promotion Model: a Sample Qualitative Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19
Patient Experience
Health Attitude
Keywords: Covid-19
patient experince
integrative treatment
qualitative study
health promotion model
Lead sponsor: Amasya University
Sponsor class: OTHER
First posted: 2021-10-22
Enrollment: 12
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals who underwent Covid-19 and used any of the integrative treatment methods constituted the population of the study. Using the criterion sampling method, individuals who underwent Covid-19 and used any of the integrative treatment methods and agreed to participate in the study constituted the sample group. In accordance with the nature of qualitative research, the study was completed with 12 people.

Brief summary: This study was conducted to examine the use of integrative treatment methods by individuals undergoing Covid-19. In this study, which was designed in the qualitative and phenomenological type, the criterion sampling method was used and 12 people were included in the sample.

Detailed description: This study was a qualitative type of phenomenological study conducted to examine the use of integrative treatment methods by individuals undergoing Covid-19. The study was completed with 12 people. The data were collected between July and October 2021. The interviews lasted for an average of 25-30 minutes. The data collected with the semi-structured interview form were analyzed by descriptive content analysis method after the interviews were over.

Eligibility criteria: Inclusion Criteria:

* individuals who underwent Covid-19 and used any of the integrative treatment methods
* agreed to participate in the study constituted the sample group.

Exclusion Criteria:

-

Primary outcomes:
measure: Using integrative treatment method
timeFrame: 15 July- October 2021
measure: Kind of integrative treatment methods
timeFrame: October 2021
Secondary outcomes:
Other outcomes:
Locations:
city: Amasya
country: Turkey
facility: Amasya University Sciences Faculty
Study officials:
affiliation: Amasya University
name: Gamze Fıskın, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Amasya University
name: Nurhan Dogan, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06973278: A Prospective Study on Clinical Effectiveness After SMILE Versus SMILE Xtra in Myopia
Official title: A Prospective Study on Clinical Effectiveness After SMILE Versus SMILE Xtra in Myopia
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Myopia
Lead sponsor: Shanghai Zhongshan Hospital
Sponsor class: OTHER
First posted: 2025-05-15
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the clinical efficacy and refractive stability of SMILE Xtra compared to SMILE in patients with myopia


Eligibility criteria: Inclusion Criteria:

1. Age between 18 and 50 years.
2. High myopia with a manifest refraction spherical equivalent (MRSE) - 6.00D～-10.00D and refractive changes within ± 0.50D in the past two years;
3. Best corrected distance visual acuity (CDVA) ≥ 20/25.
4. Preoperative refractive status is stable (myopia progression not exceeding 0.50D per year for at least 2 years).
5. Predicted residual stromal thickness (RST) ≥ 250μm after lenticule removal. 6.Soft contact lenses discontinued for at least 1 week, rigid contact lenses for at least 3 weeks, and orthokeratology lenses for at least 3 months.

Exclusion Criteria:

1. The presence of other eye diseases: keratoconus or suspected keratoconus, active keratoconjunctivitis, severe dry eye, glaucoma, retinal diseases such as retinal tears or macular degeneration, etc.,
2. The presence of significant corneal scarring or cataracts affects observation.
3. Systemic diseases such as active systemic inflammation, connective tissue diseases, other conditions that prevent

Primary outcomes:
measure: visual acuity
timeFrame: 1 week, 1 month, 6 months, 12 months，24 months and 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Zhongshan Hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT01700478: Study of the Use of Misoprostol to Decrease Bleeding During a Myomectomy
Official title: A Trial Comparing The Use Of Rectal Plus Perivascular Vasopressin With Perivascular Vasopressin Alone To Decrease Bleeding At The Time Of Myomectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hemorrhage
Keywords: Myomectomy
Lead sponsor: University Hospital of the West Indies
Sponsor class: OTHER
First posted: 2012-10-04
Enrollment: 45
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This study was done to determine if the use of a combination of preoperative rectal misoprostol 400µg used with intraoperative perivascular vasopressin is better than perivascular vasopressin used alone to decrease bleeding at myomectomy.

Detailed description: A myomectomy is a fertility sparing procedure in which fibroids are removed from the uterus. This procedure can be associated with significant blood loss which can result in significant morbidity and mortality. The drug misoprostol which has been been use in the treatment of postpartum hemorrhage was given to subset of patients who were scheduled to undergo elective myomectomy at the University hospital of the West Indies and from the private practice of the participating doctors who were invited to participate in the study. Patients were randomized to receive or not to receive pre-operative rectal misoprostol 400µg, 60 minutes before surgery. Twenty five patients received misoprostol and twenty patients did not.

Eligibility criteria: Inclusion Criteria:

* patients with symptomatic fibroids who desire future fertility and or who wish to maintain their uterus.

Exclusion Criteria:

* patients who have had previous myomectomy or previous pelvic surgery.
* patients who are severely anemic or who have significant medical conditions such as cardiac or pulmonary disease.
* patients who refuse to participate or give consent to the procedures. Patients with a known allergy to any of the study drugs.

Primary outcomes:
measure: Blood loss in millilitres
timeFrame: At the time of surgery
Secondary outcomes:
measure: A change in hemoglobin grams per decilitre
timeFrame: At baseline and 24hours after surgery
Other outcomes:
Locations:
city: Kingston
country: Jamaica
facility: University Hospital of the West Indies
Study officials:
affiliation: University Hospital of the West Indies
name: Sharifa K Frederick, dM
role: PRINCIPAL_INVESTIGATOR
References:
citation: Frederick S, Frederick J, Fletcher H, Reid M, Hardie M, Gardner W. A trial comparing the use of rectal misoprostol plus perivascular vasopressin with perivascular vasopressin alone to decrease myometrial bleeding at the time of abdominal myomectomy. Fertil Steril. 2013 Oct;100(4):1044-9. doi: 10.1016/j.fertnstert.2013.06.022. Epub 2013 Jul 19.
Clinical trial NCT03538678: Just Kwit: Mobile Intervention for Tobacco Cessation
Official title: Just Kwit: Mobile Intervention for Tobacco Cessation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Smoking Cessation
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2018-05-29
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The intervention will be use of a smartphone app to support tobacco cessation. The app's main features include sending motivational messages, displaying money saved, and allowing the user to log cravings.

Detailed description: The investigators will recruit hospitalized young adult smokers aged 18-30 interested in cessation over a six-month period. Patients will all receive a UPMC Tobacco Treatment Service counseling session focused on motivational interviewing prior to participation in the study. Upon consent, participants will then be randomized 1:1 to either standard patient-initiated follow-up or use of the Kwit app. Participants will be stratified by sex because males and females are known to have highly variable responses to existing tobacco control interventions. Investigators will systematically assess feasibility using established Likert-type items factors such as interaction, features, engagement, trust, and impact.

If a participant consents to the study, they will be given a brief survey to collect general information related to their smoking behavior. After 30 days, a follow-up survey will be conducted to assess their current smoking behavior. Participants randomized to the experimental arm will be asked additional questions about their use of the smartphone app.

Eligibility criteria: Inclusion Criteria:

* Age 18-30 smokers interested in cessation (\>5 cigarettes/day over the past 30 days)
* Must own an Apple or Android based smartphone.

Exclusion Criteria:

* Already receiving pharmacological and/or behavioral intervention or counseling for smoking cessation.

Primary outcomes:
measure: Feasibility - Helpfulness and Ease of Use of the Intervention Smartphone App
timeFrame: 1-month
measure: Feasibility - Frequency of Use
timeFrame: 1-month
Secondary outcomes:
measure: Cessation--point Prevalence Abstinence
timeFrame: 1-month
measure: Cessation--cigarettes Smoked
timeFrame: 1-month
measure: Cessation--days Smoked
timeFrame: 1-month
measure: Cessation--confidence
timeFrame: 1-month
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: UPMC
state: Pennsylvania
Study officials:
affiliation: University of Pittsburgh
name: Kar-Hai Chu, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Chu KH, Escobar-Viera CG, Matheny SJ, Davis EM, Primack BA. Tobacco cessation mobile app intervention (Just Kwit! study): protocol for a pilot randomized controlled pragmatic trial. Trials. 2019 Feb 26;20(1):147. doi: 10.1186/s13063-019-3246-2.
Clinical trial NCT02623478: A Study of a Novel Insulin Lispro Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps
Official title: Pharmacokinetics, Glucodynamics, Safety, and Tolerability of a Novel Insulin Lispro Formulation in Patients With Type 1 Diabetes Mellitus on Continuous Subcutaneous Insulin Infusion Therapy
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Diabetes Mellitus, Type 1
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2015-12-07
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: This study evaluates a new test formulation of a glucose lowering drug, insulin lispro, delivered by an insulin pump continuously under the skin. The study will be conducted in participants with type 1 diabetes mellitus to investigate how the human body processes the new test formulation and its effect on blood sugar levels when it is delivered via an insulin pump. Side effects and tolerability will be documented. The study will last about 4 to 11 weeks, including screening, lead-in and follow up. Screening is required within 28 days prior to entering the study.


Eligibility criteria: Inclusion Criteria:

* Male or female participants with Type 1 Diabetes Mellitus (T1DM) who are receiving insulin therapy via an approved insulin pump
* Have a body mass index (BMI) of 18.5 to 33 kilogram per square meter (kg/m²), inclusive, at screening
* Have blood pressure, pulse rate, electrocardiogram (ECG), blood and urine laboratory test results that are acceptable for the study
* Have had no episodes of severe hypoglycemia in the past 6 months (requiring assistance in treatment by a second party)
* Have venous access sufficient to allow for blood sampling
* Have provided written consent and are willing to follow study procedures and commit to the study duration

Exclusion Criteria:

* Are currently participating in or completed a clinical trial within the last 30 days from a clinical trial or any other type of medical research judged to be incompatible with this study
* Have previously participated or withdrawn from this study
* Have or used to have health problems, laboratory test results, blood pressure or ECG readings that, in the opinion of the doctor, could make it unsafe to participate in the study
* Had blood loss of more than 500 milliliters (mL) within the last month

Primary outcomes:
measure: Pharmacokinetics (PK): Area under the Concentration Curve (AUC) of Insulin Lispro
timeFrame: Time 0 to 5 hours post dose on Day 1 and Day 3 of each study period
Secondary outcomes:
measure: Pharmacodynamics (PD): AUC of Glucose Following a Meal
timeFrame: Time 0 to 5 hours post meal on Day 1 and Day 3 of each of study period
Other outcomes:
Locations:
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT05356078: Association Between Prescription of Antidepressants and Delirium in the Elderly : Analysis From the World Health Organization Global Database
Official title: Association Between Prescription of Antidepressants and Delirium in the Elderly : Analysis From the World Health Organization Global Database
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Antidepressive Agents
Aged
Delirium
Lead sponsor: University Hospital, Caen
Sponsor class: OTHER
First posted: 2022-05-02
Enrollment: 10000
Sex: ALL
Minimum age (years): 65
Maximum age (years): 120
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients aged 65 years and over who presented with delirium on antidepressants

Brief summary: Delirium is a frequent reason for hospitalisation of the elderly. Associations between the prescription of some medicines and the risk of delirium have already been demonstrated.

Antidepressants are widely prescribed in the elderly because of the frequency of anxiety-depressive symptoms in this population, where there are high pharmacokinetic and pharmacodynamic variability.

However, the association between antidepressants and the risk of delirium remains poorly understood.

Based on the analysis from the World Health Organization global database, the main objective of this study is to investigate the association between the different classes of antidepressants and the occurrence of the " delirium " event reported in the database.

A disproportionality analysis will be performed. It will aim to assess whether some classes of antidepressants, and within these classes some molecules, are associated with a greater risk of delirium.


Eligibility criteria: Inclusion Criteria:

* be over 65 years old
* taking antidepressants
* to have presented delirium

Exclusion Criteria:

-

Primary outcomes:
measure: Descriptive analysis of the studied population
timeFrame: 03/01/2022
measure: Analysis of the association between antidepressant classes and delirium reporting, among subjects aged 65 or older
timeFrame: 03/01/2022
Secondary outcomes:
measure: Analysis by age group
timeFrame: 03/01/2022
measure: Analysis of the co-reporting of delirium and hyponatraemia
timeFrame: 03/01/2022
measure: Analysis of the most prescribed antidepressant
timeFrame: 03/01/2022
Other outcomes:
Locations:
city: Caen
country: France
facility: Caen University Hospital, Department of Pharmacology
state: Normandie
Study officials:
References:
Clinical trial NCT00908778: A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
Official title: A Phase 3 Safety and Efficacy Study of Vitreosolve® for Four Ophthalmic Intravitreal Injections For Inducing Posterior Vitreous Detachment in Retinopathy Patients.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Diabetic Retinopathy
Keywords: Diabetic Retinopathy
Lead sponsor: Vitreoretinal Technologies, Inc.
Sponsor class: INDUSTRY
First posted: 2009-05-27
Enrollment: 160
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this study is to determine the safety and efficacy of Vitreosolve® in diabetic retinopathy patients.


Eligibility criteria: Inclusion Criteria:

* Subjects with a history of systemic diabetes(type I,or II)
* Subject with a documented history of Non- proliferative Diabetic Retinopathy(NPDR)
* Subjects with no or partial PVD at baseline exam in study eye.

Exclusion Criteria:

* Subjects with retinal pathology in the study eye other then (NPDR)
* Subjects with high myopia in the study eye
* Subjects who have monocular vision or central lateral vision of 20/200 or worse BCVA in the non-study eye.
* Subjects with an aphakic study eye or if pseudophakic, cataract extraction surgery less then 6 months prior to study enrollment.
* Subjects that have either vitrectomy surgery, intavitreal injections, or laser treatments in the study eye.

Primary outcomes:
measure: Ultrasound, OCT, and clinical exam
timeFrame: 6 months
Secondary outcomes:
measure: Ultrasound ,OCT ,Safety, and Clinical Exam
timeFrame: 6 months
Other outcomes:
Locations:
city: Vizag
country: India
facility: LVPEI
state: AP
city: Kochi
country: India
facility: Amrita
city: San Lucas
country: Mexico
facility: La Ceguera
state: Coyoacan
city: Mexico City
country: Mexico
facility: Conde De Valenciana
state: DF
city: Monterrey
country: Mexico
facility: Hidalgo
state: Neuvo Leon
Study officials:
affiliation: APEC, Hospital La Ceguera
name: Hugo Quiroz-Mercado, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Colorado, Denver
name: Naresh Mandova, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05876078: DORAYA-HF OUS Assessment of the Doraya Catheter for the Treatment of ADHF Patients With Insufficient Response to Diuretics
Official title: DORAYA-HF EU: Assessment of the Doraya Catheter for the Treatment of Volume Overload in Acute Heart Failure Patients With Insufficient Response to Diuretics
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Acute Decompensated Heart Failure
Keywords: ADHF
Lead sponsor: Revamp Medical Ltd.
Sponsor class: INDUSTRY
First posted: 2023-05-25
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study objective is to evaluate the feasibility of the Doraya Catheter and measure clinical performance and safety endpoints, in ADHF patients deemed to have insufficient diuretic response.


Eligibility criteria: Inclusion Criteria:

1. Subject is hospitalized with primary diagnosis of ADHF.
2. N-terminal-pro-brain natriuretic peptide (NT-proBNP) ≥1,000 pg/m orvBNP≥250 pg/mL.
3. Evidence of fluid overload.
4. Subject insufficiently responds to IV diuretic therapy

Exclusion Criteria:

Systolic blood pressure \< 80 mmHg at the time of screening. 2. Acute myocardial infarction or acute coronary syndrome or cardiogenic shock or pleurocentesis within past 14 days or cardiovascular intervention within past 14 days. 3. Complex congenital heart disease (e.g., Tetralogy of Fallot subjects, single ventricle physiology).

4. Known active myocarditis, hypertrophic obstructive cardiomyopathy, infiltrative cardiomyopathy (e.g., amyloidosis), constrictive pericarditis or cardiac tamponade.

5. Severe Aortic valvular disorder (i.e., hemodynamically relevant valvular diseases such as severe stenosis \\severe regurgitation) or Severe mitral disease with planned intervention.

6. Evidence of active systemic infection documented by either one of the following: fever \>38°C/100°F, or ongoing uncontrolled infection (i.e., inflammatory parameters not decreasing despite \> 48 hours of antibiotic treatment).

7. Moribund subject or subject with severe or deteriorating damage in more than 3 critical body systems, based on investigator's clinical judgement.

Primary outcomes:
measure: Serious Adverse Events
timeFrame: 30 day post Doraya procedure
measure: Urine Output
timeFrame: 24 hours pre Doraya deployment, during Doraya indwelling period, and for 24 hours after Doraya removal
Secondary outcomes:
Other outcomes:
Locations:
city: Tbilisi
country: Georgia
facility: LLC Bokhua Memorial Cardiovascular Center
city: Tbilisi
country: Georgia
facility: LTD Israel Georgian Medical Research Clinic Helsicore
city: Warsaw
country: Poland
facility: Narodowy Instytut Kardiologii Stefana kardynała Wyszyńskiego Państwowy Instytut Badawczy
city: Wrocław
country: Poland
facility: Mikulicz-Radecki University Teaching Hospital in Wrocław
city: Banská Bystrica
country: Slovakia
facility: SUSCCH
city: Bratislava
country: Slovakia
facility: CINRE, s.r.o.
city: Barcelona
country: Spain
facility: Hospital clinic de Barcelona
Study officials:
References:
Clinical trial NCT06922578: Clinical and Radiographic Success of Pulpotomy Using Neoputty Mineral Trioxide Aggregate Versus Pulpectomy Using Endoflas In Primary Molars With Irreversible Pulpitis: A Randomized Controlled Trial
Official title: Clinical and Radiographic Success of Pulpotomy Using Neoputty Mineral Trioxide Aggregate Versus Pulpectomy Using Endoflas In Primary Molars With Irreversible Pulpitis: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Pulpitis - Irreversible
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2025-04-10
Enrollment: 66
Sex: ALL
Minimum age (years): 4
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this randomized clinical trial is to evaluate the clinical and radiographic success of pulpotomy using Neoputty MTA vital primary molars diagnosed with symptomatic irreversible pulpitis.

The main question it aims to answer is:

Will Neoputty MTA pulpotomy have higher clinical and radiographic success in comparison to Endoflas pulpectomy in primary molars with irreversible pulpitis?


Eligibility criteria: Inclusion Criteria:

* Children with spontaneous pain lasting a few seconds to several hours.
* Pain is intensified by thermal stimulus and persists after its removal.
* Pulp hemorrhage after performing access cavity and deroofing of pulp chamber showing reddish pink healthy pulp tissue.
* Radicular pulp health is verified by achieving hemostasis within six minutes of compression using a cotton pellet with 2% sodium hypochlorite.
* Absence of peri-apical or inter-radicular radiolucency, widening of periodontal ligament space, internal or external root resorption.

Exclusion Criteria:

* Unrestorable primary molars.
* Primary molars with uncontrolled pulp hemorrhage or pulp necrosis.
* Medically compromised patients who have systemic disease.
* Uncooperative children who refuse treatment.

Primary outcomes:
measure: postoperative pain
timeFrame: within 24 hours, after 1 week, 3, 6, 9, and 12 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: assistant lecturer
name: DR
role: PRINCIPAL_INVESTIGATOR
References: